Explain Missed Targets in Your Next Raise
Missing Q1 targets doesn't kill a fundraise , showing up in April without a coherent explanation of why does. The founders who convert Q1 misses into Q2 funding run a structured autopsy: they separate execution gaps from thesis failures, build a numerical variance tree, connect every miss to a specific Q2 adjustment with measurable success criteria, and surface the hidden wins buried in the data. Done right, this process makes you more fundable than a founder who hit their numbers but can't explain why , because investors are ultimately betting on judgment and learning velocity, not a single quarter's output. If you're raising in Q2 and missed Q1, the work you do this week in late March determines whether you walk into partner meetings looking rigorous or reactive.
- A Q1 miss is only fatal to your fundraise if you can't articulate it precisely, investors can fund execution gaps, but they cannot fund a broken thesis, so your first job is to diagnose which one you actually have.
- Building a numerical variance tree for every missed target (breaking down pipeline, conversion, cycle time, and churn separately) transforms a defensive conversation into a diagnostic one, and demonstrates the measurement discipline VCs need to defend you to their partners.
- Every identified variance must map directly to a Q2 adjustment with a specific action, a budget or resource commitment, and a measurable success metric, a Q2 plan that says 'work harder' after a Q1 miss is not a plan investors can evaluate.
- Q1 misses frequently come packaged with hidden advantages, lower CAC, stronger retention, sharper ICP clarity, or reduced burn, and founders who surface these wins and reframe their Q2 narrative around them consistently raise faster than those who lead with apology.
- Run a base and downside forecast before the meeting. Show which milestone is still affordable and which expense you can change if revenue falls below plan.

When the quarter closes below plan, put the actual figure and the target on the same page. Break the difference down so an investor can see which part came from demand, conversion, timing or churn.
Here's what most founders get wrong: they treat Q1 misses as problems to apologize for. The sharp founders? They treat them as data points that de-risk Q2.
The difference isn't spin. It's structure. And if you're planning to raise in Q2, the work you do this week to dissect what happened in Q1 will determine whether investors see you as reactive or rigorous.
Why Q1 Misses Actually Matter Right Now
VCs are building their Q2 pipelines right now. We covered this in detail in why April pipelines start in March, but the short version: partners are in planning mode, budget discussions are happening, and they're actively looking for companies that can articulate clear momentum narratives heading into the next quarter.
A Q1 miss doesn't disqualify you. But showing up in April with a deck that pretends Q1 didn't happen, or worse, buries the miss in vague language? That kills your credibility before you get to the traction slide.
The founders who convert Q1 misses into Q2 funding do something specific: they run an autopsy, not a postmortem. They don't just analyze what went wrong, they extract investable insights that make their Q2 plan more credible than if they'd hit their targets.
The Q1 Autopsy Framework
This isn't about self-flagellation or defensive justification. It's about building a systematic narrative that shows investors you understand your business at a level that makes you more fundable, not less.
Step 1: Separate the Miss from the Thesis
First question: did you miss your targets because your fundamental thesis is wrong, or because your execution had gaps?
This matters because investors can fund execution gaps. They can't fund broken theses.
If you projected 50 enterprise deals and closed 12, that's not necessarily a thesis problem. If you projected 50 deals at $50K ACV and it turns out your ICP can only afford $15K, that's a different conversation.
Write this down explicitly:
- The thesis assumption: What did we believe about the market/customer/product?
- What we learned: What does the Q1 data actually tell us?
- Thesis status: Validated, invalidated, or needs refinement?
Show which assumptions failed and what you changed in response. Keep the missed target visible and separate evidence that the original idea still holds from evidence that only changed the operating plan.
Step 2: Build Your Variance Tree
Take every meaningful Q1 target you missed and break down why with numerical precision.
Let's say you targeted $200K MRR and hit $135K. Don't stop at "slower sales cycle than expected." Build the tree:
A hypothetical variance review could start with these lines.
- Pipeline fell 30% below target after the company moved advertising spend to product.
- Conversion finished 15% above target. The team would need to test how much came from onboarding or qualification.
- The sales cycle ran 22 days longer than projected. Check whether budget approvals account for the delay.
- Churn ended at the planned 3.2%.
Now you have something investors can actually evaluate. You're not defensive, you're diagnostic. And crucially, you're showing them you measure things.
This is exactly the kind of rigor VCs look for when they're building their investment memos. If you can't articulate your variance with this level of detail, they can't defend you to their partners.
Step 3: Extract the Q2 Adjustments
This is where most founders lose the thread. They do the analysis, identify the problems, and then... their Q2 plan is just "work harder and hope."
The autopsy framework requires you to connect each variance directly to a specific Q2 adjustment with measurable criteria.
Using the MRR example above:
Hypothetical Q2 response. At $18,000 a month for acquisition and $400 per qualified lead, the plan implies 45 qualified leads a month, or 135 over a full quarter. Calculate customer acquisition cost from how many of those leads actually become paying customers.
Q1 Variance: Sales cycle extended by 22 days due to new procurement layer Q2 Adjustment: Implement procurement toolkit (templates, ROI calculator, comparison matrix) deployed to all prospects at demo stage, plus SDR training on early budget qualification Success Metric: Average cycle reduced to 35 days by end of Q2
Notice what this does: it shows investors you're not just identifying problems, you're building systems to solve them. And you're doing it with the same rigor they'd expect from a portfolio company.
Step 4: Identify the Hidden Wins
Here's what separates experienced founders from first-timers: they know that Q1 misses often come packaged with Q2 advantages.
Go back through your Q1 data and actively look for:
- Efficiency improvements: Did you acquire customers at lower CAC than projected, even if volume was down?
- Product validation: Did retention or engagement metrics outperform, even if top-line growth lagged?
- Market intelligence: Did you learn something about your ICP that makes your Q2 targeting more precise?
- Team capabilities: Did you hire or develop skills that will compound in Q2?
If usage improves while fewer customers sign up, chart those two changes over the same period. Then show whether the change in usage came from a larger share of active users or from the same handful of accounts doing more.
The investors didn't care about the user count. They cared about unit economics and founder learning velocity.
Step 5: Stress-Test Your Q2 Plan
Now take your Q2 projections and run them through the autopsy lens before you put them in your deck.
For each Q2 target, ask:
- What assumption from Q1 am I carrying forward?
- Which of those assumptions did Q1 actually validate?
- What's my margin of error based on Q1 variance?
- If I miss by the same percentage I missed in Q1, does my business still work?
Build a base case and two hypothetical downside cases, for example at 75% and 50% of planned revenue. Check which expenses can move and when cash falls below the amount needed for the next milestone.
Investors will stress-test you in the meeting anyway. If you've already done it and can walk them through your thinking, you look like someone who manages risk. If they catch you off guard, you look like you're hoping your way to success.
Putting It in Your Deck
You don't need a "Q1 Autopsy" slide (please don't make one). But this framework should inform three specific parts of your pitch:
The traction narrative. In a hypothetical example, the company planned for $200,000 MRR and reached $135,000. Explain which deals moved, how that changed acquisition costs and what you expect to test next quarter.
Your milestones slide: Your Q2 targets should directly connect to your Q1 learnings. If investors see your plan, they should be able to trace the logic. This is where sequencing your milestones becomes critical.
Your use of funds: If you've done this framework properly, your Q2 adjustments should map cleanly to how you'll deploy capital. That's what makes the round fundable.
The March Timing Advantage
If you're reading this in late March 2026, you have a specific window that won't be open in April.
VCs are wrapping Q1 reporting to their LPs, planning their Q2 deployment, and building their pipelines for the next 90 days. Companies that show up now with clear Q1 data and credible Q2 plans get categorized as "rigorous operators who know their business." Companies that show up in mid-April hoping no one asks about Q1 get categorized as "avoiding hard conversations."
We wrote about this dynamic in the context of this week's deployment window, but it applies even more sharply if you're coming off a miss. The partners who are planning Q2 right now are specifically looking for founders who can turn data into strategy.
What This Looks Like in Practice
Start the review with the shortfall and write one line explaining what actually changed.
For a hypothetical sales team, a later start date leaves fewer people prospecting at the beginning of the quarter. Use the actual start dates and ramp period to estimate pipeline, then show the cash impact if hires start later again.
Use the next rehearsal to check whether an investor can connect the staffing change to the revised pipeline forecast.
If the reader needs another number to trace the difference, put it in the variance note or the supporting model.
Your Next 72 Hours
If you're planning to raise in Q2 and you missed Q1 targets:
- Block four hours this week and run through the five-step autopsy framework above
- Update your deck to reflect your Q1 learnings (don't hide them, weaponize them)
- Stress-test your Q2 plan with the same rigor you'd expect from a partner meeting
- Start your outreach now, not in April, the pipeline you build this week determines your Q2 close rate
And if you want to see how your current deck holds up against what investors are actually evaluating in late March, run it through Deckmetric's pitch analysis. You'll get specific feedback on whether your traction narrative and metrics story are landing the way you think they are.
Q1 misses don't kill fundraises. Founders who can't explain them do.
Turn your variance into credibility, and Q2 becomes your strongest quarter yet.
Sebastian Scheplitz Founder, Shepard&Young Creator, Deckmetric
Last updated

